News Despite Trump price concerns, JP Morgan event anticipates M&... 2017 could be a bumper year for M&A - but Trump's price control threats dominate
News Johnson & Johnson back in 'exclusive' talks to buy Actelion Deal expected to be worth around $30 billion.
News Sanofi outbids J&J for Actelion merger - reports Reports suggest Sanofi could pay $30 billion for Swiss biotech.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
